Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
Digital Holographic Microscopy for biomarker detection in cancer
“In the near future”, Zahra El-Schich says, “you could have a HoloMonitor in every clinic. You could also customize cancer treatment for every patient by just using a simple tumor test.” Find out how.
Kallelse till årsstämma i Phase Holographic Imaging PHI (publ)
Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542-7811, kallas härmed till årsstämma onsdagen den 26 september 2018 kl. 17.00 i bolagets lokaler, Scheelevägen 22 i Lund.
New CEO commentary: “Understanding Skin Cancer”
PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence.
Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer
Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.
Fighting cancer at an early stage
Using nanoparticles and HoloMonitor technology Prof. Anette Gjörloff Wingren and her team aim to develop an early screening method that detects cancer by a simple blood test.
PHI´s new software available for customer delivery
In this first version of App Suite three common analyzes are included: cell proliferation, cell motility, and cell quality control. App Suite will be rapidly expanded with additional applications. HoloMonitor® App Suite 2.0 is scheduled to be released to customers in Q4 2018.
Kommuniké från extra bolagsstämma i Phase Holographic Imaging PHI AB (publ)
Igår, den 18 juni 2018, hölls extra bolagsstämma i Phase Holographic Imaging PHI AB (publ). Stämman röstande enhälligt för föreslagna beslut gällande nyemission.
PHI and BioSpherix sign co-marketing agreement
Phase Holographic Imaging (PHI) and BioSpherix recently signed a collaboration agreement aiming to co-market the companies’ complementary product lines. BioSpherix, NY USA, manufactures and markets advanced cell incubators.
Biostock interview with CEO Peter Egelberg
New CEO commentary — “Redefining aging with HoloMonitor”
In the CEO commentary “Redefining aging with HoloMonitor” Peter Egelberg comments on the promising research results that were recently reported by Australian television.